Curis Provides First Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Source: prnewswire.com
📰 Roche Group News
Page 39 - Roche Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Roche Group. Real-time updates on events, politics, business and more.
AC Immune SA: AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)
Source: finanznachrichten.de
Bristol Myers Squibb appoints new CEO
Bristol Myers Squibb’s leadership team is set to reshuffle, with Christopher Boerner becoming it’s new CEO in late 2023.
United States Theodorer Samuels Katherine Welles Shutterstock Adam Lenkowsky Christopher Boerner Giovanni Caforio
Source: europeanpharmaceuticalreview.com
F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase
Source: finanznachrichten.de
F. Hoffmann-La Roche Ltd: Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect
United States Gazyva Gazyvaro Nathalie Altermatt Actemra Roactemra Mabthera Rituxan Thomas Schinecker
Source: finanznachrichten.de
Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Source: investegate.co.uk
Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Investegate announcements from F. Hoffmann-La Roche Ltd, New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Source: investegate.co.uk
F. Hoffmann-La Roche Ltd: New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or 'wet' age-related macular degeneration (nAMD) and diabetic macular edema
Source: finanznachrichten.de
New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration and diabetic... | April 25, 2023
Source: marketscreener.com
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema ... | April 25, 2023
United States Levi Garraway Roger Goldberg Clinical Development Program Association For Research Global Product Development
Source: marketscreener.com